GlassScriptPhysician profile
Richard H Roe
NPI 1043412489
$23,125.31
in general payments reported to CMS, 2019-2025
17 companies · $2,667 in 2025
The $2,667 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,703 · 2020: $1,741 · 2021: $764 · 2022: $1,198 · 2023: $13K · 2024: $2,198 · 2025: $2,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $5,148 · Travel and Lodging: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,340.00 |
| Food and Beverage | $5,148.32 |
| Travel and Lodging | $1,229.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $20,504.59 | 2019-2025 | Constellation, Unity, Ngenuity |
| Genentech USA, INC. | $571.76 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $525.15 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $444.25 | 2019-2023 | Eylea |
| Abbvie INC. | $238.29 | 2022-2024 | Ozurdex |
| Eyepoint US, INC. | $177.30 | 2020-2022 | |
| Allergan, INC. | $143.85 | 2019-2022 | |
| Sandoz INC. | $137.41 | 2024 | Cimerli |
| Novartis Pharmaceuticals Corporation | $128.34 | 2019 | |
| Astellas Pharma US INC | $56.15 | 2023-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $47.51 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Genentech, INC. | $44.43 | 2023 | Vabysmo, Susvimo |
| Glaukos Corporation | $35.89 | 2024 | Ce-Marked Kxla System |
| Oyster Point Pharma, INC. | $30.35 | 2022 | |
| Biogen, INC. | $26.38 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $13.66 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.